Dyslipidemia in Type 2 Diabetes (0767-034)

Dyslipidemia Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00547274
• Other study ID #: 0767-034
• Secondary ID: 2007_635MK-0767-
• Status: Terminated
• Phase: Phase 3
• First received: October 19, 2007
• Last updated: June 11, 2015
• Start date: July 2003
• Est. completion date: November 2003

Study information

• Verified date: June 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 111
• Est. completion date: November 2003
• Est. primary completion date: November 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Men and non-pregnant females

• Age greater than or equal to 21 years

• Stop current diabetes therapy (if applicable)

• Stop current statin therapy (if applicable)

Exclusion Criteria:

• History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin

• Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks

• Patients requiring treatment with corticosteroids for more than 14 consecutive days

• Patients taking warfarin or warfarin-like anti-coagulants

• Patients undergoing surgery within 30 days of Visit 1

• Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease

• Patients with history of pancreatitis or uncontrolled high blood pressure

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Diabetes Mellitus, Type II
• Dyslipidemia
• Dyslipidemias

Intervention

Drug:
• MK0767

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.